Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Stem Cell Paracrine Signaling for Treatment of Premature Ovarian Insufficiency

Polonio AM., García-Velasco JA., Herraiz S.

Clinical Trial on Immune Modulation, published in Front Endocrinol (Lausanne) (2020) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Front Endocrinol (Lausanne) (2020)
Reported sample size
—
Source database
Europe PMC
PMID
33716956
PMCID
PMC7943922
DOI
10.3389/fendo.2020.626322
Citations
22

Abstract (original English)

Premature ovarian insufficiency is a common disorder affecting young women and represents the worst-case ovarian scenario due to the substantial impact on the reproductive lifespan of these patients. Due to the complexity of this condition, which is not fully understood, non-effective treatments have yet been established for these patients. Different experimental approaches are being explored and strategies based on stem cells deserve special attention. The regenerative and immunomodulatory properties of stem cells have been successfully tested in different tissues, including ovary. Numerous works point out to the efficacy of stem cells in POI treatment, and a wide range of clinical trials have been developed in order to prove safety and effectiveness of stem cells therapy-in diminished ovarian reserve and POI women. The main purpose of this review is to describe the state of the art of the treatment of POI involving stem cells, especially those that use mobilization of stem cells or paracrine signaling.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Stem CellsAnimalsHumansDisease Models, AnimalTreatment OutcomeStem Cell TransplantationParacrine CommunicationFemaleClinical Trials as TopicPrimary Ovarian Insufficiency

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research